These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11489683)

  • 1. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
    Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
    Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
    See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
    J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA; Tyrrell CJ;
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
    Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
    Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
    Wirth MP; See WA; McLeod DG; Iversen P; Morris T; Carroll K;
    J Urol; 2004 Nov; 172(5 Pt 1):1865-70. PubMed ID: 15540740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of adjuvant hormonal therapy.
    Mcleod DG
    Urology; 2002 Sep; 60(3 Suppl 1):13-20; discussion 21. PubMed ID: 12231039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
    Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
    Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
    Iversen P; Tammela TL; Vaage S; Lukkarinen O; Lodding P; Bull-Njaa T; Viitanen J; Hoisaeter P; Lundmo P; Rasmussen F; Johansson JE; Persson BE; Carroll K;
    Eur Urol; 2002 Sep; 42(3):204-11. PubMed ID: 12234503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
    See W; Iversen P; Wirth M; McLeod D; Garside L; Morris T
    Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
    Iversen P; Johansson JE; Lodding P; Lukkarinen O; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Carroll K;
    J Urol; 2004 Nov; 172(5 Pt 1):1871-6. PubMed ID: 15540741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
    Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
    Tyrrell CJ; Payne H; Tammela TL; Bakke A; Lodding P; Goedhals L; Van Erps P; Boon T; Van De Beek C; Andersson SO; Morris T; Carroll K
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):476-83. PubMed ID: 15380582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.